BI
EVLO

BVF Inc’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

BVF Inc’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-65,000
Closed -$6.85M – 74
2020
Q3 		$6.85M Hold
65,000
– – 0.37% 50
2020
Q2 		$6.37M Buy
+65,000
New +$5.69M 0.39% 46

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BVF Inc's EVLO Position: Q4 2020 in Review

BVF Inc sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2020, closing a stake of 65,000 shares — an estimated $6.85M sold.

BVF Inc first reported a position in EVLO in Q2 2020 and held it in 2 quarters. The position peaked at $6.85M in Q3 2020. 49 funds tracked by Wall St. Rank hold EVLO as of Q4 2020.

  • BVF Inc reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • BVF Inc sold 65,000 Evelo Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $6.85M.
  • BVF Inc first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • BVF Inc's Evelo Biosciences, Inc. Common Stock position peaked at $6.85M in Q3 2020.
  • 49 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2020.

Based on BVF Inc's 13F filing for Q4 2020, filed 12 Feb 2021.